Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium

NEXT STORY
Marketing authorization granted for darolutamide in Japan
PREV STORY
Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Elevations RTC Creates a Safe Place For Struggling Teens

author_avatar
NASDAQ Market News

Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff

author_avatar
NASDAQ Market News

eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone

SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in ...

author_avatar
NASDAQ Market News